Report Code: A06540 | Pages: 329 | Jun 2020 | 6171 Views | ||
Author(s) : Surabhi P , Onkar S | Tables: 190 | Charts: 62 |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Oral Antibiotics Market
Request Now !The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.
Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.
The virus that causes COVID-19 is from the family of viruses called Coronaviridae and antibiotics do not work against them. However, some people who are affected by Covid-19 can also develop a bacterial infection as a complication. In this case, health care providers recommend antibiotics. Hence, the impact of Covid-19 on oral antibiotics industry is expected to be moderate.
There is an increase in demand for antibiotics, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.
The global oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type, and region. On the basis of class, it is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in the global oral antibiotics market include Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.
Depending on class, the market is categorized into the beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018. The segment is the major revenue contributor, owing to its broad-spectrum of activity. A broad-spectrum antibiotic fights both gram-negative and gram-positive bacteria as well as is effective on the multiple groups of bacterial infections. However, quinolone segment is expected to witness highest CAGRs during the forecast period, owing to its broad spectrum of activity and they are effective against a wide range of bacteria.
On the basis of application, the CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies. The urinary acquired tract infections segment was the highest contributor to the market in 2018, and expected to witness CAGR of 2.0% during the forecast period, as it is the most common hospital acquired infection accounting for almost 40% of all nosocomial infections and females are more likely to acquire UTI every year as compared to males. In addition, diabetic patients are also more prone to UTIs, mostly owing to abnormalities in immune function.
On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms. However, the synthetic segment is projected to show fastest growth during the forecast period, due to the rising need of synthetic membrane-targeted antibiotics due to the antimicrobial resistance. The synthetic antibiotics have various advantages over existing antibiotics such as a broad spectrum of activity, no cross-resistance with the existing antibiotics, rapid bactericidal activity, and a low probability for developing resistance.
Region wise, Asia-Pacific accounted for nearly two-fifths of the global market share in 2018 and is expected to remain dominant throughout the forecast period. This region is the world’s largest consumer of antibiotics, owing to large number of antibiotics consumption, easy availability of antibiotics, and rise in sales of antibiotics without prescription. However, LAMEA is expected to experience the highest growth rate during the forecast period. This is attributed to easy obtainability of over-the-counter antibiotics as well as there are no legislations or restrictions on their use in this region.
Key Benefits For Stakeholders
Oral Antibiotics Market Report Highlights
Aspects | Details |
---|---|
By Class |
|
By Application |
|
By DRUG ORIGIN |
|
By Spectrum Of Activity |
|
By DRUG TYPE |
|
By Region |
|
Key Market Players | GLAXOSMITHKLINE PLC, MERCK & CO., INC., PFIZER INC., NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.), MYLAN N.V., SANOFI, TEVA PHARMACEUTICAL INDUSTRIES LTD., F. HOFFMANN-LA ROCHE LTD., ABBOTT LABORATORIES, ALLERGAN PLC |
Loading Table Of Content...
This section provides various opinions of top-level CXOs in the oral antibiotics market. According to several interviews conducted, the field of oral antibiotics is gaining popularity, owing to its ease of use and convenience for patients.
As per CXOs, rise in infectious diseases, growth in initiatives by pharma companies to enhance antibiotics R&D, and technological innovations in oral antibiotics significantly boost the growth of the oral antibiotics market. However, development of antibiotic resistance, driven by misuse of antibiotics, and increase in drug approval costs are expected to hinder the market growth.
In addition, rise in consumption of antibiotics in low and middle-income countries (LMICs), increase in prevalence of infectious diseases, development of novel approaches for new antibiotics to treat bacterial infections, and large number of clinical trials are projected to drive the market growth during the forecast period.
The CXOs further added that the market is saturated and is growing at a steady rate in developed nations. Asia-Pacific is expected to remain dominant during the forecast period, owing to increase in consumption of antibiotics, lower cost of antibiotics, and high prevalence of bacterial infections in developing countries. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, owing to rise in antimicrobial resistance, which leads pharmaceutical companies toward R&D for next generation antibiotics. In addition, wide availability of advanced systems supplements the growth of the market.
A. The total value of oral antibiotics market was $ 18,861.70 million in 2019.
A. The forecast period in the report is from 2020-2027.
A. The market value of oral antibiotics market in 2020 was $24,256.10 million.
A. The base year calculated is 2018 in the report.
A. As per the key industry leaders, rise in incidence of infectious diseases cases, Increase in consumption in low-and middle-income countries (LMICs)increasing R&D initiatives to develop novel technologies and Development of novel approaches will drive the oral antibiotics market
A. Development of novel approaches in the market is expected to drive the market growth during the forecast period.
A. The growth % of the Autoinjectors market is 2.7%.
A. Beta lactam and lactamase inhibitors segment holds the maximum market share.
Start reading instantly.
This Report and over 54,961+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers